Table 1.
Histopathological and clinical data
| Category | Patients |
GPR49-mRNA level in zmol/molecule HPRT |
GPR49Δ5-mRNA level in zmol/molecule HPRT | ||
|---|---|---|---|---|---|
| ≤1.07*10-5 | > 1.07*10-5 | ≤7.6*10-6 | > 7.6*10-6 | ||
| Total | 77 | 39 | 38 | 39 | 38 |
| P = 0.429 | P = 0.212 | ||||
| Men | 35 | 16 | 19 | 15 | 20 |
| Women | 42 | 23 | 19 | 24 | 18 |
| Tumor stage | P = 0.023* | P = 0.005* | |||
| I | 10 | 1 | 9 | 0 | 10 |
| II | 33 | 21 | 12 | 21 | 12 |
| III | 26 | 12 | 14 | 13 | 13 |
| IV | 8 | 5 | 3 | 5 | 3 |
| Tumor type | P = 0.194 | P = 0.166 | |||
| liposarcoma | 19 | 6 | 13 | 5 | 14 |
| fibrosarcoma/malignant fibrous histiocytoma | 20 | 9 | 11 | 11 | 9 |
| neurogenic sarcoma | 6 | 3 | 3 | 3 | 3 |
| rhabdomyosarcoma/leiomyosarcoma | 22 | 15 | 7 | 14 | 8 |
| Other STS | 10 | 6 | 4 | 6 | 4 |
| Tumor resection | P = 0.377 | P = 0.172 | |||
| radical (R0) | 51 | 24 | 27 | 23 | 28 |
| not radical (R1) | 26 | 15 | 11 | 16 | 10 |
| Patients at follow-up | |||||
| alive | 36 | 15 | 21 | 13 | 23 |
| dead | 41 | 24 | 17 | 26 | 15 |
| Localization | P = 0.444 | P = 0.207 | |||
| extremities | 49 | 25 | 24 | 26 | 23 |
| thorax | 6 | 2 | 4 | 1 | 5 |
| head | 1 | 0 | 1 | 0 | 1 |
| abdomen | 19 | 10 | 9 | 10 | 9 |
| multiple | 2 | 2 | 0 | 2 | 0 |
| Metastasis | P = 0.291 | P = 0.025* | |||
| M0 | 21 | 9 | 12 | 7 | 14 |
| M1 | 29 | 17 | 12 | 19 | 10 |
| Age of tumor onset | P = 0.218 | P = 0.039* | |||
| age (mean) | 59.9 | 55.4 | 61.4 | 53.9 | |
| Kaplan-Meier analysis | P = 0.056 | P = 0.004* | |||
| mean survival (months) | 50.1 ± 6.5 | 80.3 ± 10.7 | 45.8 ± 6.4 | 86.2 ± 10.9 | |
| Univariate Cox's Regression | P = 0.06 | P = 0.006* | |||
| RR | 1.8 | 2.5 | |||
| CI | 0.97-3.5 | 1.3-4.8 | |||
| Multiv. Cox's-Regression | P = 0.12 | P = 0.026* | |||
| RR | 1.8 | 2.6 | |||
| CI | 0.9-4.0 | 1.1-6.0 | |||